Disc Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 49.03% HC Wainwright & Co. $70 → $70 Reiterates Buy → Buy 06/17/2024 49.03% BMO Capital $50 → $
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright analyst Douglas Tsao maintains $Disc Medicine(IRON.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 39.0%
Buy Rating Affirmed: Strong Phase 2 Results and Strategic FDA Engagement Bolster Confidence in Disc Medicine's Pipeline
Disc Medicine(IRON.US) Director Sells US$9,253.3 in Common Stock
$Disc Medicine(IRON.US)$ Director White William Richard sold 201 shares of common stock on Jul 1, 2024 at an average price of $46.0363 for a total value of $9,253.3.Source: Announcement What is statem
Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Disc Medicine Insider Bought Shares Worth $3,000,024, According to a Recent SEC Filing
Mona Ashiya, Director, on June 17, 2024, executed a purchase for 83,334 shares in Disc Medicine (IRON) for $3,000,024. Following the Form 4 filing with the SEC, Ashiya has control over a total of 235,
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $79
Stifel analyst Benjamin Burnett maintains $Disc Medicine(IRON.US)$ with a buy rating, and adjusts the target price from $72 to $79.According to TipRanks data, the analyst has a success rate of 35.3% a
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Cuts Target Price to $50
BMO Capital analyst Evan Seigerman maintains $Disc Medicine(IRON.US)$ with a buy rating, and adjusts the target price from $70 to $50.According to TipRanks data, the analyst has a success rate of 0.0%
BMO Capital Reiterates Outperform on Disc Medicine, Raises Price Target to $70
BMO Capital analyst Evan Seigerman reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $50 to $70.
Express News | Disc Medicine Inc : Wedbush Raises Target Price to $57 From $43
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $57 to $70
On Jun 15, major Wall Street analysts update their ratings for $Disc Medicine(IRON.US)$, with price targets ranging from $57 to $70.BMO Capital analyst Evan Seigerman maintains with a buy rating, and
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results
U.S. stocks traded mixed toward the trading, with the Dow Jones index falling around 0.2% on Friday.The Dow traded down 0.24% to 38,554.69 while the NASDAQ rose 0.07% to 17,680.01. The S&P 500 also fe
Wedbush Raises Disc Medicine Price Target to $57 From $43, Maintains Outperform Rating
Disc Medicine (IRON) has an average rating of outperform and price targets ranging from $40 to $85, according to analysts polled by Capital IQ. Price: 46.14, Change: +6.98, Percent Change: +17.81
Disc Medicine On Track for Largest Percent Increase Since December 2022-- Data Talk
Disc Medicine, Inc. (IRON) is currently at $47.40, up $8.25 or 21.05% --Would be highest close since March 28, 2024, when it closed at $62.26 --On pace for largest percent increase since Dec. 30, 20
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for
12 Health Care Stocks Moving In Friday's Intraday Session
GainersCyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million. CNS Pharma (NASDAQ:C
Disc Medicine +17%, Prices $178 Million Common Stock Offering; Shares Rise
Disc Medicine (IRON) said Friday that it has priced an underwritten offering of about 4.9 million common shares at $36 per share for expected gross proceeds of about $178 million. Net proceeds will be
Gold Gains 1%; US Consumer Sentiment Falls In June
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Friday.The Dow traded down 0.63% to 38,403.11 while the NASDAQ fell 0.07% to 17,655.10. The S&
Disc Medicine Shares Jump 18% After Latest Aurora Clinical Trial Data
By Sabela Ojea Shares of Disc Medicine on Friday jumped after the company said it received positive data from its phase 2 clinical trial Aurora to treat erythropoietic protoporphyria with ibitopertin
Express News | Disc Medicine Shares Are Trading Higher. The Company Announced the Presentation of Data at the European Hematology Association 2024 Congress and Announced an Underwritten Offering